Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Bernstein Bank
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Fintel on MSN11h
Leerink Partners Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...
Jefferies Sticks to Their Buy Rating for Regeneron (REGN)
In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.